Raymond James Financial
SLDB icon

Raymond James Financial’s Solid Biosciences SLDB Stock Holding History

Raymond James Financial’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,835
Closed -$13.8K – 6483
2025
Q2 		$13.8K Buy
+2,835
New +$10K ﹤0.01% 5761

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's SLDB Position: Q3 2025 in Review

Raymond James Financial sold out of Solid Biosciences (SLDB) in Q3 2025, closing a stake of 2,835 shares — an estimated $13.8K sold.

Raymond James Financial first reported a position in SLDB in Q2 2025 and held it in 1 quarter. The position peaked at $13.8K in Q2 2025. 127 funds tracked by Wall St. Rank hold SLDB as of Q3 2025.

  • Raymond James Financial reported no remaining Solid Biosciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,835 Solid Biosciences shares in Q3 2025, an estimated $13.8K.
  • Raymond James Financial first reported a position in Solid Biosciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Solid Biosciences position peaked at $13.8K in Q2 2025.
  • 127 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.